BONDURANT STUART 4
4 · PHARMACEUTICAL PRODUCT DEVELOPMENT INC · Filed Jan 4, 2011
Insider Transaction Report
Form 4
BONDURANT STUART
Director
Transactions
- Award
Common Stock
2011-01-03+2,355→ 20,199 total
Holdings
- 14,053
Stock Options (to buy)
Exercise: $19.19From: 2009-05-20Exp: 2019-05-20→ Common Stock (14,053 underlying) - 6,485
Stock Options (to buy)
Exercise: $41.32From: 2008-05-21Exp: 2018-05-20→ Common Stock (6,485 underlying) - 5,650
Stock Options (to buy)
Exercise: $22.98From: 2005-05-18Exp: 2015-05-17→ Common Stock (5,650 underlying) - 6,341
Stock Options (to buy)
Exercise: $32.67From: 2007-05-16Exp: 2017-05-16→ Common Stock (6,341 underlying) - 10,496
Stock Options (to buy)
Exercise: $24.52From: 2010-05-20Exp: 2020-05-20→ Common Stock (10,496 underlying) - 4,113
Stock Options (to buy)
Exercise: $34.18From: 2006-05-17Exp: 2016-05-16→ Common Stock (4,113 underlying)
Footnotes (1)
- [F1]Exercise price and share amounts reflect an anti-dilution adjustment made in connection with the June 14, 2010 spin-off of Furiex Pharmaceuticals, Inc.